JP2001507703A - 細胞にインプリンティングの正常パターンを復元するための組成物および方法 - Google Patents
細胞にインプリンティングの正常パターンを復元するための組成物および方法Info
- Publication number
- JP2001507703A JP2001507703A JP53025498A JP53025498A JP2001507703A JP 2001507703 A JP2001507703 A JP 2001507703A JP 53025498 A JP53025498 A JP 53025498A JP 53025498 A JP53025498 A JP 53025498A JP 2001507703 A JP2001507703 A JP 2001507703A
- Authority
- JP
- Japan
- Prior art keywords
- imprinting
- cells
- drug
- cancer
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.真核細胞において正常なインプリンティングを復元する方法であって、前 記細胞をゲノムインプリンティングに影響を及ぼす有効量の薬剤と接触させる工 程を含み、前記有効量は異常なインプリンティングを示す細胞を標的にするのに 十分であるが一般的な細胞毒性を示さないことを特徴とする方法。 2.前記真核細胞は哺乳類細胞である請求の範囲第1項記載の方法。 3.前記薬剤はDNAのメチル化、ヒストンの脱アセチル化、トポイソメラー ゼIIおよびDNA合成に対する阻害剤からなる群から選択される請求の範囲第 1項記載の方法。 4.前記薬剤は5−アザ−2’−デオキシシトジン、トリコスタチンA、ラン カシジン、ベンゼンアミン、シクロヘキサン酢酸、ブループラチナウラシル、メ チル 13−ヒドロキシ−15−オキソ−カウレノエート、スルホニウム、ユー ホルニンD、オクタデシルホスホリルクロリン、グニジマクリンおよびアスピク ラマイシンHCLから成る群から選択される請求の範囲第3項記載の方法。 5.前記接触工程は必要とする哺乳類に有効量の薬剤組成物を投与する工程を 含む請求の範囲第2項記載の方法。 6.前記投与工程は組織への投与である請求の範囲第5項記載の方法。 7.前記薬剤はDNAのメチル化およびヒストンの脱アセチル化の阻害剤から なる群から選択される請求の範囲第5項記載の方法。 8.前記薬剤は5−アザ−2’−デオキシシトジン、トリコスタチンA、ラン カシジン、ベンゼンアミン、シクロヘキサン酢酸、ブループラチナウラシル、メ チル 13−ヒドロキシ−15−オキソ−カウレノエート、スルホニウム、ユー ホルニンD、オクタデシルホスホリルクロリン、グニジマクリンおよびアスピク ラマイシンHCLから成る群から選択される請求の範囲第7項記載の方法。 9.異常なインプリンティングを伴う疾患の治療または予防をする方法であっ て、必要とする哺乳類にゲノムインプリンティングに関与する有効量の薬剤を投 与する工程を含むことを特徴とする方法。 10.前記疾患はウィルムス腫瘍、肺癌、パラガングリオーマ腫瘍、前立腺癌 、 乳癌、結腸癌、膀胱癌、白血病、卵巣癌、腎臓癌および網膜芽細胞腫から成る群 から選択される請求の範囲第9項記載の方法。 11.前記疾患は組織または器官の悪性な増殖である請求の範囲第9項記載の 方法。 12.前記薬剤はDNAのメチル化およびヒストンの脱アセチル化の阻害剤か ら成る群から選択される請求の範囲第9項記載の方法。 13.前記薬剤は5−アザ−2’−デオキシシトジン、トリコスタチンA、ラ ンカシジン、ベンゼンアミン、シクロヘキサン酢酸、ブループラチナウラシル、 メチル 13−ヒドロキシ−15−オキソ−カウレノエート、スルホニウム、ユ ーホルニンD、オクタデシルホスホリルクロリン、グニジマクリンおよびアスピ クラマイシンHCLから成る群から選択される請求の範囲第12項記載の方法。 14.標的とする器官または組織中で癌を発症する哺乳類の傾向を診断する方 法であって、前記の器官または組織からの細胞のインプリンティングパターンを 判定する工程を含むことを特徴とする方法。 15.前記の器官または組織は結腸、乳房、前立腺、肝臓、肺、膀胱、腎臓、 卵巣および精巣からなる群から選択される請求の範囲第14項記載の方法。 16.ゲノムインプリンティングに関与する薬剤を同定する方法であって、薬 剤を細胞に投与する工程および前記細胞のインプリンティングパターンを判定す る工程を含むことを特徴とする方法。 17.インプリンティングに関与する薬剤を含む薬剤組成物であって、ゲノム インプリンティングに影響を及ぼす有効量の薬剤を含み、前記有効量は異常なイ ンプリンティングを示す細胞を標的にするのに十分であるが一般的な細胞毒性を 示さないことを特徴とする組成物。 18.前記薬剤はDNAのメチル化およびヒストンの脱アセチル化の阻害剤か らなる群から選択される請求の範囲第17項記載の方法。 19.前記薬剤は5−アザ−2’−デオキシシトジン、トリコスタチンA、ラ ンカシジン、ベンゼンアミン、シクロヘキサン酢酸、ブループラチナウラシル、 メチル 13−ヒドロキシ−15−オキソ−カウレノエート、スルホニウム、ユ ーホルニンD、オクタデシルホスホリルクロリン、グニジマクリンおよびアスピ クラマイ シンHCLから成る群から選択される請求の範囲第18項記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3409596P | 1996-12-30 | 1996-12-30 | |
US60/034,095 | 1996-12-30 | ||
PCT/US1997/023991 WO1998029108A2 (en) | 1996-12-30 | 1997-12-29 | Compositions and methods for restoring a normal pattern of imprinting to cells |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008272942A Division JP2009072197A (ja) | 1996-12-30 | 2008-10-23 | 細胞にインプリンティングの正常パターンを復元するための組成物および方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2001507703A true JP2001507703A (ja) | 2001-06-12 |
JP2001507703A5 JP2001507703A5 (ja) | 2005-08-11 |
JP4913270B2 JP4913270B2 (ja) | 2012-04-11 |
Family
ID=21874277
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53025498A Expired - Lifetime JP4913270B2 (ja) | 1996-12-30 | 1997-12-29 | 細胞にインプリンティングの正常パターンを復元するための組成物および方法 |
JP2008272942A Pending JP2009072197A (ja) | 1996-12-30 | 2008-10-23 | 細胞にインプリンティングの正常パターンを復元するための組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008272942A Pending JP2009072197A (ja) | 1996-12-30 | 2008-10-23 | 細胞にインプリンティングの正常パターンを復元するための組成物および方法 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0969822B1 (ja) |
JP (2) | JP4913270B2 (ja) |
AT (1) | ATE235190T1 (ja) |
AU (1) | AU5722398A (ja) |
CA (1) | CA2276306C (ja) |
DE (1) | DE69720283T2 (ja) |
DK (1) | DK0969822T3 (ja) |
ES (1) | ES2195196T3 (ja) |
WO (1) | WO1998029108A2 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020520675A (ja) * | 2017-05-22 | 2020-07-16 | リセン インプリンティング ダイアグノステックス,インク.Lisen Imprinting Diagnostics,Inc. | モデル、診断方法及びその応用 |
JP2021531833A (ja) * | 2018-08-01 | 2021-11-25 | リセン インプリンティング ダイアグノステックス ウーシー カンパニー リミテッドLisen Imprinting Diagnostics Wuxi Co., Ltd. | 甲状腺腫瘍の良性度・悪性度を検出するためのグレード分類モデルおよびその応用 |
JP2022516392A (ja) * | 2018-07-13 | 2022-02-28 | リセン インプリンティング ダイアグノステックス ウーシー カンパニー リミテッド. | 肺腫瘍の良性度・悪性度を検出するためのグレード分類モデルおよびその応用 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6803195B1 (en) * | 1999-07-02 | 2004-10-12 | Ramot At Tel-Aviv University Ltd. | Facile detection of cancer and cancer risk based on level of coordination between alleles |
GB0107267D0 (en) * | 2001-03-23 | 2001-05-16 | Babraham Inst | Diagnostic method for determining the methylation state of cloned embryos |
US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
AU2002952944A0 (en) * | 2002-11-27 | 2002-12-12 | Human Genetic Signatures Pty Ltd | Restoration of methylation states in cells |
EP1641936B1 (en) | 2003-06-17 | 2010-08-04 | Human Genetic Signatures PTY Ltd. | Methods for genome amplification |
CA2537810C (en) | 2003-09-04 | 2012-12-18 | Human Genetic Signatures Pty Ltd | Nucleic acid detection assay |
US8168777B2 (en) | 2004-04-29 | 2012-05-01 | Human Genetic Signatures Pty. Ltd. | Bisulphite reagent treatment of nucleic acid |
JP4980219B2 (ja) | 2004-09-10 | 2012-07-18 | ヒューマン ジェネティック シグネチャーズ ピーティーワイ リミテッド | インターカレート型擬似ヌクレオチド(ipn)を含有するインターカレーティング核酸(ina)を含む増幅ブロッカー |
KR101293713B1 (ko) | 2004-12-03 | 2013-08-12 | 휴먼 제네틱 시그너처스 피티와이 엘티디 | 시토신의 화학적 변형에 의한 미생물 핵산의 단순화 방법 |
CN101203618B (zh) | 2005-05-26 | 2013-03-13 | 人类遗传标记控股有限公司 | 使用含有非常规碱基的引物的等温链置换扩增 |
CN101292046B (zh) | 2005-09-14 | 2013-03-13 | 人类遗传标记控股有限公司 | 健康状态的测定法 |
GB0607063D0 (en) | 2006-04-07 | 2006-05-17 | Cellcentric Ltd | Compositions and methods for epigenetic modification of nucleic acid sequences in vivo |
CN101918595A (zh) | 2007-11-27 | 2010-12-15 | 人类遗传标记控股有限公司 | 用于扩增和复制亚硫酸氢盐修饰的核酸的酶 |
US9732375B2 (en) | 2011-09-07 | 2017-08-15 | Human Genetic Signatures Pty. Ltd. | Molecular detection assay using direct treatment with a bisulphite reagent |
CN112313345B (zh) * | 2018-05-18 | 2024-02-20 | 立森印迹诊断技术(无锡)有限公司 | 一种通过活检细胞样本诊断癌症的方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58177949A (ja) * | 1982-04-12 | 1983-10-18 | Takeda Chem Ind Ltd | ランカシジン群抗生物質包接化合物 |
JPS61176523A (ja) * | 1985-01-30 | 1986-08-08 | Teruhiko Beppu | 制癌剤 |
EP0631584A4 (en) * | 1991-02-28 | 1998-07-01 | Dana Farber Cancer Inst Inc | DIAGNOSIS AND THERAPY OF CANCER. |
EP0627436A1 (en) * | 1991-08-08 | 1994-12-07 | TSUMURA & CO. | Carcinostatic compound and production thereof |
US5356903A (en) * | 1993-04-22 | 1994-10-18 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolines |
-
1997
- 1997-12-29 JP JP53025498A patent/JP4913270B2/ja not_active Expired - Lifetime
- 1997-12-29 WO PCT/US1997/023991 patent/WO1998029108A2/en active IP Right Grant
- 1997-12-29 AU AU57223/98A patent/AU5722398A/en not_active Abandoned
- 1997-12-29 DE DE69720283T patent/DE69720283T2/de not_active Expired - Lifetime
- 1997-12-29 ES ES97953486T patent/ES2195196T3/es not_active Expired - Lifetime
- 1997-12-29 EP EP97953486A patent/EP0969822B1/en not_active Expired - Lifetime
- 1997-12-29 CA CA002276306A patent/CA2276306C/en not_active Expired - Lifetime
- 1997-12-29 DK DK97953486T patent/DK0969822T3/da active
- 1997-12-29 AT AT97953486T patent/ATE235190T1/de not_active IP Right Cessation
-
2008
- 2008-10-23 JP JP2008272942A patent/JP2009072197A/ja active Pending
Non-Patent Citations (9)
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2020520675A (ja) * | 2017-05-22 | 2020-07-16 | リセン インプリンティング ダイアグノステックス,インク.Lisen Imprinting Diagnostics,Inc. | モデル、診断方法及びその応用 |
US11734818B2 (en) | 2017-05-22 | 2023-08-22 | Lisen Imprinting Diagnostics Wuxi Co., Ltd | Model, diagnostic method, and application thereof |
JP2022516392A (ja) * | 2018-07-13 | 2022-02-28 | リセン インプリンティング ダイアグノステックス ウーシー カンパニー リミテッド. | 肺腫瘍の良性度・悪性度を検出するためのグレード分類モデルおよびその応用 |
JP2021531833A (ja) * | 2018-08-01 | 2021-11-25 | リセン インプリンティング ダイアグノステックス ウーシー カンパニー リミテッドLisen Imprinting Diagnostics Wuxi Co., Ltd. | 甲状腺腫瘍の良性度・悪性度を検出するためのグレード分類モデルおよびその応用 |
Also Published As
Publication number | Publication date |
---|---|
JP4913270B2 (ja) | 2012-04-11 |
CA2276306A1 (en) | 1998-07-09 |
DE69720283D1 (de) | 2003-04-30 |
WO1998029108A3 (en) | 1999-02-18 |
EP0969822A2 (en) | 2000-01-12 |
ATE235190T1 (de) | 2003-04-15 |
DK0969822T3 (da) | 2003-07-21 |
CA2276306C (en) | 2009-12-15 |
EP0969822B1 (en) | 2003-03-26 |
ES2195196T3 (es) | 2003-12-01 |
DE69720283T2 (de) | 2004-01-29 |
WO1998029108A2 (en) | 1998-07-09 |
JP2009072197A (ja) | 2009-04-09 |
AU5722398A (en) | 1998-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009072197A (ja) | 細胞にインプリンティングの正常パターンを復元するための組成物および方法 | |
Falls et al. | Genomic imprinting: implications for human disease | |
JP5416660B2 (ja) | Dnaメチル化の阻害剤 | |
BR112021002622A2 (pt) | biomarcadores para terapia de câncer | |
Yu et al. | An antibody to Notch3 reverses the skeletal phenotype of lateral meningocele syndrome in male mice | |
ITMI952539A1 (it) | Classe di oligonucleotidi fosfodiesterici ad attivita' citotossica composizioni farmaceutiche che li contengono e loro uso | |
Longo et al. | The RASopathies: Biology, genetics and therapeutic options | |
TW201420105A (zh) | 黏膜治癒促進劑 | |
WO2016106357A1 (en) | Combination of raf inhibitors and aurora kinase inhibitors | |
AU2005202456B2 (en) | Compositions and methods for restoring a normal pattern of imprinting to cells | |
AU782463B2 (en) | Compositions and methods for restoring a normal pattern of imprinting to cells | |
EP1332756A2 (en) | Compositions and methods for restoring a normal pattern of imprinting to cells | |
US11642362B2 (en) | Methods of inhibiting cell proliferation and METTL8 activity | |
US10166251B2 (en) | STAT5a and its functional tumor suppressor analogs for treatment of malignancies expressing NPM/ALK and other oncogenic kinases | |
KR101486248B1 (ko) | Dna 메틸화 저해제를 포함하는 상염색체 우성 다낭신 개선 또는 치료용 약학 조성물 | |
US20230183814A1 (en) | Predictive biomarkers for onvansertib treatment | |
Grundy et al. | Characterization of the breakpoints in unbalanced t (5; 11)(p15; p15) constitutional chromosome translocations in two patients with beckwith-wiedemann syndrome using fluorescence in situ hybridisation. | |
Goossens | Modif ing the modifier: disco ering mechanisms of SMCHD1 mediated chromatin repression | |
US20130309249A1 (en) | Materials and methods for the prophylactic treatment of a pre-malignant condition | |
Smith et al. | Characterization of Porcine Models of Autosomal Recessive Polycystic Kidney Disease: PO1517 | |
KR101693186B1 (ko) | PAN-ErbB 억제제의 암 치료 효과 예측에 관한 정보 제공 방법 | |
WO2021255518A1 (en) | Compositions and methods for treating acute myeloid leukemia | |
Mekker | Physiological roles of the DNA demethylation-associated proteins Gadd45a and Ing1 | |
Hasanali | CD30 regulation by chemical and viral agents and the resulting effect on anti-CD30 therapy | |
Cottini et al. | Genomics in Multiple Myeloma: From Conventional Cytogenetics to Novel Whole-Genome Sequencing Approaches |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041220 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080624 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080916 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081027 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081023 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090210 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090508 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090615 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090610 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090825 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091224 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100325 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20100617 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120119 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150127 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |